Artivion (AORT) Change in Accured Expenses (2010 - 2026)
Artivion (AORT) posted Change in Accured Expenses of -$8.7 million for Q1 2026, down 192.83% on a QoQ basis from $9.4 million in Q4 2025, and up 45.78% year-over-year from -$6.0 million in Q1 2025.
Artivion (AORT) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Artivion's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$8.7 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 45.78% year-over-year to -$8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 million (up 258.38% YoY) and the FY2025 annual result came in at $2.2 million, down 77.02% from the prior year.
- Change in Accured Expenses was -$8.7 million for Q1 2026 at Artivion, down from $9.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $14.7 million in Q4 2024 and bottomed at -$16.1 million in Q1 2025.
- A 5-year average of $487058.8 and a median of $794000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 308.81% — and 2023, when it soared 436.02%.
- Artivion's Change in Accured Expenses stood at $2.9 million in 2022, then jumped by 40.26% to $4.1 million in 2023, then surged by 260.89% to $14.7 million in 2024, then plunged by 36.37% to $9.4 million in 2025, then slumped by 192.83% to -$8.7 million in 2026.
- Business Quant data shows AORT's Change in Accured Expenses at -$8.7 million in Q1 2026, $9.4 million in Q4 2025, and -$967000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 145.10 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 21.07 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -250.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Artivion | 1.25 Bn | 1.19 Bn | 75.45 Mn | -8.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.70 Mn |
| Mar 31, 2026 | -8.70 Mn |
| Dec 31, 2025 | 9.38 Mn |
| Dec 31, 2025 | 9.38 Mn |
| Sep 30, 2025 | -967,000.00 |
| Sep 30, 2025 | -967,000.00 |
| Jun 30, 2025 | 9.83 Mn |
| Jun 30, 2025 | 9.83 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Dec 31, 2024 | 14.74 Mn |
| Dec 31, 2024 | 14.74 Mn |
| Sep 30, 2024 | 794,000.00 |
| Sep 30, 2024 | 794,000.00 |
| Jun 30, 2024 | 3.19 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | -9.22 Mn |
| Mar 31, 2024 | -9.22 Mn |
| Dec 31, 2023 | 4.08 Mn |
| Dec 31, 2023 | 4.08 Mn |